Natco Pharma Ltd.

Natco Pharma has filed an Abbreviated New Drug Application (ANDA) for generic version of Lapatimb Ditosylate tablets in 250mg strength. The company is first to file applicant for this product, possibly leading to 180 days marketing exclusivity.

The innovator product (Tykerb tablets by Glaxo), used for the treatment of breast cancer, clocked revenues of $114 million in the USA last year. Natco has partnered with Lupin for marketing of the said product.

Following this, Natco has five IV challenges on hand, with four first to file opportunities.

Natco Pharma was promoted by V C Nannapaneni in the year 1981 as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.